{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:24:47Z","timestamp":1760487887670,"version":"build-2065373602"},"reference-count":67,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PPMI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Parkinson\u2019s disease (PD) is characterized not only by motor dysfunction but also by widespread degeneration across cortico-striatal, limbic, and cortical circuits. Mounting evidence suggests that tau and \u03b1-synuclein pathology underlie these processes, though how these proteinopathies translate into affective and cognitive outcomes remains uncertain. Depression and anxiety are highly prevalent in PD, yet the biological correlates of these affective disturbances are poorly defined. Methods: This is a retrospective analysis of existing data from the Parkinson\u2019s Progression Markers Initiative (PPMI). Montreal Cognitive Assessment (MoCA), geriatric depression scale (GDS), and State-Trait Anxiety Inventory (STAI) were used to assess cognition, depression, and anxiety in PD, respectively. The CSF biomarkers evaluated were A\u03b242, t-tau, and p-tau181, using Elecsys electro-chemiluminescence immunoassays on the cobas e601 platform (Roche Diagnostics). Results: From the 4380 patients who had GDS information, the MoCA test was collected from 438 patients, and 445 from the GDS test for depression, and the STAI screening for anxiety. There were no significant differences in biomarker levels between patients with depression (GDS \u2265 5) and those without (GDS &lt; 5), nor between patients with anxiety (STAI &gt; 40) and those with lower anxiety scores (STAI \u2264 40). In contrast, cognitive outcomes showed clear associations. Patients with cognitive impairment (MoCA &lt; 26) demonstrated higher levels of pTau (p = 0.02) and tTau (p = 0.01), as well as elevated pTau\/A\u03b242 (p = 0.003) and tTau\/A\u03b242 (p = 0.002) ratios compared to those with MoCA \u2265 26. In multivariate analysis, both pTau\/A\u03b242 &gt; 0.022 (OR 4.64, 95% CI 1.67\u201313.8) and tTau\/A\u03b242 &gt; 0.26 (OR 4.18, 95% CI 1.6\u201311.5) remained significantly associated with cognitive decline. In a longitudinal analysis in the first 3 years of follow-up, cognition in PD remained lower than in controls, while CSF p-tau and A\u03b242 remained higher in controls. Conclusions: In our cohort, no associations were found between CSF biomarkers and depression or anxiety, underscoring that mood disturbances in PD are likely mediated by alternative mechanisms such as monoaminergic dysregulation, neuroinflammation, and psychosocial factors. By contrast, cognitive performance (MoCA) was clearly linked to tau-related pathology, rather than \u03b1-synuclein or A\u03b242 alone. While A\u03b242 and \u03b1-synuclein remain useful for staging and assessing global disease risk, our findings highlight the specificity of tau-related pathology for cognitive outcomes in PD.<\/jats:p>","DOI":"10.3390\/biomedicines13102478","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:48:21Z","timestamp":1760420901000},"page":"2478","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dissociation of Clinical Outcomes and CSF Proteinopathy Biomarkers in Parkinson\u2019s Disease: Cognitive\u2013Affective Dissociation with Specificity for Tau"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-0405","authenticated-orcid":false,"given":"Jo\u00e3o Paulo","family":"Mota Telles","sequence":"first","affiliation":[{"name":"Department of Neurology, University of S\u00e3o Paulo, S\u00e3o Paulo 01246-903, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4112-6473","authenticated-orcid":false,"given":"Lucas","family":"Camargo","sequence":"additional","affiliation":[{"name":"Spaulding Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-3835","authenticated-orcid":false,"given":"Anna Carolyna","family":"Gianloren\u00e7o","sequence":"additional","affiliation":[{"name":"Spaulding Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02138, USA"},{"name":"Laboratory of Neuroscience and Neurological Rehabilitation, Physical Therapy Department, Federal University of S\u00e3o Carlos, S\u00e3o Carlos 13565-905, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-7526","authenticated-orcid":false,"given":"Felipe","family":"Fregni","sequence":"additional","affiliation":[{"name":"Spaulding Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cong, S., Xiang, C., Zhang, S., Zhang, T., Wang, H., and Cong, S. (2022). Prevalence and clinical aspects of depression in Parkinson\u2019s disease: A systematic review and meta-analysis of 129 studies. Neurosci. Biobehav. Rev., 141.","DOI":"10.1016\/j.neubiorev.2022.104749"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41531-023-00512-1","article-title":"The experience of Anxiety for people with Parkinson\u2019s disease","volume":"9","author":"Blundell","year":"2023","journal-title":"NPJ Park. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: The inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/01.wnl.0000268695.63392.10","article-title":"The impact of depressive symptoms in early Parkinson disease","volume":"69","author":"Ravina","year":"2007","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1750-3639.2010.00373.x","article-title":"Profile of cognitive impairment in Parkinson\u2019s disease","volume":"20","author":"Watson","year":"2010","journal-title":"Brain Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Global Parkinson\u2019s Disease Survey (GPDS) Steering Committee (2002). Factors impacting on quality of life in Parkinson\u2019s disease: Results from an international survey. Mov. Disord., 17, 60\u201367.","DOI":"10.1002\/mds.10010"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1498756","DOI":"10.3389\/fnagi.2024.1498756","article-title":"Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: Findings from the Global Burden of Disease Study 2021","volume":"16","author":"Luo","year":"2024","journal-title":"Front Aging Neurosci."},{"key":"ref_9","first-page":"e27750","article-title":"Depression in Parkinson\u2019s Disease: A Narrative Review","volume":"14","author":"Chikatimalla","year":"2022","journal-title":"Cureus."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41531-021-00247-x","article-title":"Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with freezing of gait: An exploratory analysis","volume":"7","author":"McKay","year":"2021","journal-title":"NPJ Park. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: Convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Liampas, I., Kyriakoulopoulou, P., Siokas, V., Tsiamaki, E., Stamati, P., Kefalopoulou, Z., Chroni, E., and Dardiotis, E. (2024). Apolipoprotein E Gene in \u03b1-Synucleinopathies: A Narrative Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031795"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10603","DOI":"10.1523\/JNEUROSCI.0608-14.2014","article-title":"Exogenous \u03b1-synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release","volume":"34","author":"Ronzitti","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15414","DOI":"10.1523\/JNEUROSCI.4742-09.2009","article-title":"Cav1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons","volume":"29","author":"Putzier","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/mds.27823","article-title":"Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?","volume":"34","author":"Wong","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fan, T.S., Liu, S.C., and Wu, R.M. (2021). Alpha-Synuclein and Cognitive Decline in Parkinson Disease. Life, 11.","DOI":"10.3390\/life11111239"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Miquel-Rio, L., Sarri\u00e9s-Serrano, U., Pavia-Collado, R., Meana, J.J., and Bortolozzi, A. (2023). The Role of \u03b1-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020541"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","article-title":"A protein factor essential for microtubule assembly","volume":"72","author":"Weingarten","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1073\/pnas.0609303104","article-title":"Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer\u2019s neurodegeneration","volume":"104","author":"Li","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1126\/science.1105681","article-title":"Axonopathy and transport deficits early in the pathogenesis of Alzheimer\u2019s disease","volume":"307","author":"Stokin","year":"2005","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0140-6736(86)92134-3","article-title":"Defective brain microtubule assembly in Alzheimer\u2019s disease","volume":"2","author":"Iqbal","year":"1986","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajp.2017.01.025","article-title":"The neurobiology of depression: An integrated view","volume":"27","author":"Dean","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","article-title":"CSF tau and tau\/A\u03b242 predict cognitive decline in Parkinson\u2019s disease","volume":"21","author":"Liu","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kwon, E.H., Tennagels, S., Gold, R., Gerwert, K., Beyer, L., and T\u00f6nges, L. (2022). Update on CSF Biomarkers in Parkinson\u2019s Disease. Biomolecules, 12.","DOI":"10.3390\/biom12020329"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson Progression Marker Initiative (PPMI)","volume":"95","author":"Marek","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jad.2019.08.053","article-title":"Usefulness of the 15-item geriatric depression scale (GDS-15) for classifying minor and major depressive disorders among community-dwelling elders","volume":"259","author":"Shin","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.2044-8260.1990.tb00906.x","article-title":"Utility and validity of the STAI with anxiety disorder patients","volume":"29","author":"Oei","year":"1990","journal-title":"Br. J. Clin. Psychol."},{"key":"ref_31","first-page":"698","article-title":"Derivation of cutoffs for the Elecsys(\u00ae) amyloid \u03b2 (1-42) assay in Alzheimer\u2019s disease","volume":"10","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2-amyloid (1\u201342) in human cerebrospinal fluid","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00415-018-9100-8","article-title":"Amyloid-\u03b2 and Parkinson\u2019s disease","volume":"266","author":"Lim","year":"2019","journal-title":"J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/mds.25866","article-title":"The spectrum of cognitive impairment in Lewy body diseases","volume":"29","author":"Goldman","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00005072-199804000-00005","article-title":"Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson\u2019s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity","volume":"57","author":"Irizarry","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"23179","DOI":"10.1074\/jbc.M802223200","article-title":"Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death","volume":"283","author":"Sugeno","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bpa.12344","article-title":"Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson\u2019s Disease and Dementia with Lewy Bodies","volume":"27","author":"Power","year":"2017","journal-title":"Brain Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4161\/auto.19371","article-title":"Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway","volume":"8","author":"Klucken","year":"2012","journal-title":"Autophagy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1474-4422(04)00827-0","article-title":"Lewy-body formation is an aggresome-related process: A hypothesis","volume":"3","author":"Olanow","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1126\/science.1129462","article-title":"Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson\u2019s models","volume":"313","author":"Cooper","year":"2006","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.parkreldis.2020.09.030","article-title":"Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis","volume":"80","author":"Chin","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/CON.0000000000000309","article-title":"Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia","volume":"22","author":"Gomperts","year":"2016","journal-title":"Continuum"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/ene.14032","article-title":"The value of cerebrospinal fluid \u03b1-synuclein and the tau\/\u03b1-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology","volume":"27","author":"Tysnes","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jnc.14809","article-title":"Parkinson\u2019s disease biomarkers based on \u03b1-synuclein","volume":"150","author":"Fayyad","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.seizure.2009.04.006","article-title":"Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure","volume":"18","author":"Palmio","year":"2009","journal-title":"Seizure"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40478-024-01913-w","article-title":"Distinct subcellular localization of tau and alpha-synuclein in lewy body disease","volume":"13","author":"Fischer","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: Which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00401-015-1525-x","article-title":"Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo","volume":"131","author":"Vasconcelos","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"fcaa090","DOI":"10.1093\/braincomms\/fcaa090","article-title":"Differential cross-seeding properties of tau and \u03b1-synuclein in mouse models of tauopathy and synucleinopathy","volume":"2","author":"Williams","year":"2020","journal-title":"Brain Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/brain\/awae372","article-title":"Patterns of tau, amyloid and synuclein pathology in ageing, Alzheimer\u2019s disease and synucleinopathies","volume":"148","author":"Colloby","year":"2025","journal-title":"Brain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11064-025-04399-7","article-title":"Unravelling the Proteinopathic Engagement of \u03b1-Synuclein, Tau, and Amyloid Beta in Parkinson\u2019s Disease: Mitochondrial Collapse as a Pivotal Driver of Neurodegeneration","volume":"50","author":"Sahoo","year":"2025","journal-title":"Neurochem. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cger.2019.09.012","article-title":"Depression and Anxiety in Parkinson Disease","volume":"36","author":"Ray","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0891988703256053","article-title":"Recognition and treatment of depression in Parkinson\u2019s disease","volume":"16","author":"Weintraub","year":"2003","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2470547017703993","DOI":"10.1177\/2470547017703993","article-title":"The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress","volume":"1","author":"Patriquin","year":"2017","journal-title":"Chronic Stress"},{"key":"ref_58","first-page":"S11","article-title":"Stress, norepinephrine and depression","volume":"26","author":"Leonard","year":"2001","journal-title":"J Psychiatry Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.bbi.2016.03.004","article-title":"Associations of low grade inflammation and endothelial dysfunction with depression\u2014The Maastricht Study","volume":"56","author":"Schram","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15294145.2009.10773593","article-title":"Depression: An evolutionarily conserved mechanism to terminate separation distress? A review of aminergic, peptidergic, and neural network perspectives","volume":"11","author":"Watt","year":"2009","journal-title":"Neuropsychoanalysis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2015.09.002","article-title":"Depressive-like phenotype induced by AAV-mediated overexpression of human \u03b1-synuclein in midbrain dopaminergic neurons","volume":"273","author":"Caudal","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41380-019-0585-z","article-title":"Prospective biomarkers of major depressive disorder: A systematic review and meta-analysis","volume":"25","author":"Kennis","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/jnnp.2003.027060","article-title":"Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson\u2019s disease","volume":"75","author":"Fregni","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41398-024-02739-9","article-title":"Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: A systematic review and meta-analysis","volume":"14","author":"Twait","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rotter, A., Lenz, B., Pitsch, R., Richter-Schmidinger, T., Kornhuber, J., and Rhein, C. (2019). Alpha-Synuclein RNA Expression is Increased in Major Depression. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20082029"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbi.2021.03.020","article-title":"Hippocampal alpha-synuclein mediates depressive-like behaviors","volume":"95","author":"Du","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid \u03b1-Synuclein in prodromal and early Parkinson\u2019s disease","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2478\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:22:05Z","timestamp":1760422925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biomedicines13102478"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13102478","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}